Anti–vascular endothelial growth factor therapy

PharmAbcine to Participate in BIO-Europe 2022

Retrieved on: 
Monday, September 26, 2022
Therapy, Diabetic retinopathy, Immunology, RIT, Ophthalmology, Neoplasm, Mass flow (life sciences), IND, VISTA, Company, DME, Industry, Glioblastoma, Triple-negative breast cancer, Blood, Myeloid-derived suppressor cell, Anti–vascular endothelial growth factor therapy, KOSDAQ, Clinical trial, Drug development, Research, AMD, Public relations, Globe, MDSC, Pharmaceutical industry, Vaccine, Radioimmunotherapy

DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place in Leipzig, Germany on October 24 26, 2022.

Key Points: 
  • DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place in Leipzig, Germany on October 24 26, 2022.
  • This year, more than 4,000 global biopharma executives from more than 60 nations around the globe are expected to participate in the event.The event will also be held virtually on November 2 4, 2022.
  • The Company expects to submit an IND for Phase I ophthalmology clinical trial in the second half of 2022.
  • PharmAbcine also has unique knowhow in the area of the antibody production, early drug development, and clinical development.

PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention

Retrieved on: 
Wednesday, May 11, 2022
Drug development, Anti–vascular endothelial growth factor therapy, IND, Mass flow (life sciences), DME, Company, Neoplasm, VISTA, Jefferies, Patient, Triple-negative breast cancer, Diabetic retinopathy, Immunology, Myeloid-derived suppressor cell, Therapy, Ophthalmology, Clinical trial, Public relations, MDSC, Conference, AMD, Glioblastoma, Research, Phase, Medical device, Pharmaceutical industry, Vaccine

At Jefferies Global Healthcare Conference, Dr. Yoo will hold meetings with registered members of the investor community to look for investment opportunities and to discuss the current trends in drug development and healthcare sector.

Key Points: 
  • At Jefferies Global Healthcare Conference, Dr. Yoo will hold meetings with registered members of the investor community to look for investment opportunities and to discuss the current trends in drug development and healthcare sector.
  • The registered members will include leading global executives, institutional investors, and private equity investors.
  • After the meetings at Jefferies, Dr. Yoo and Dr. Park will participate in BIO International Convention to meet with global pharmaceutical companies.
  • They will introduce PharmAbcine's core technology and pipeline assets to discuss potential licensing and co-development opportunities with global biotechs and pharmaceutical companies participating in the event.

Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access

Retrieved on: 
Thursday, March 3, 2022
Marketing, Terminology, PHSA, Ophthalmology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Leadership, Patient, BLA, Mab, Risk, Food, Eye, VEGF, Retinal, SVP, Annual report, Biologics license application, Security (finance), U.S. Securities and Exchange Commission, FDA, Growth, Therapy, Bleeding, Blood, Retina, Goal, SEC, BRVO, COVID-19, Senior, AMD, Bevacizumab, Anti–vascular endothelial growth factor therapy, Cerebral edema, DME, Diosynth, Physician, Nasdaq, GLOBE, Pharmaceutical industry, Outlook, Genentech

ISELIN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced that Alicia Tozier has been appointed as Senior Vice President, Marketing and Market Access.

Key Points: 
  • ISELIN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced that Alicia Tozier has been appointed as Senior Vice President, Marketing and Market Access.
  • Ms. Tozier is a proven global commercialization leader with expertise across nine ophthalmology disease areas, and she has launched combination products spanning multiple modalities including medical devices, digital therapeutics and pharmaceuticals.
  • She will be responsible for leading the global commercial strategy, including marketing and market access, to ensure launch readiness across customers and channels.
  • In her role as SVP, Marketing and Market Access at Outlook Therapeutics, Ms. Tozier will report directly to Chief Commercial Officer Mr. Evanson and work cross-functionally with the leadership team.

Vascular Endothelial Growth Factor Inhibitors Pipeline Insight 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 24, 2022
Health, Pharmaceutical, Anti–vascular endothelial growth factor therapy, Therapy, Acquisition, Technology, Route, ROA, Route of administration, NDA, Administration, Pharmaceutical industry

The "Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Vascular Endothelial Growth Factor Inhibitors pipeline landscape.
  • Companies and academics are working to assess challenges and seek opportunities that could influence Vascular Endothelial Growth Factor Inhibitors R&D.
  • The therapies under development are focused on novel approaches to treat/improve Vascular Endothelial Growth Factor Inhibitors.

Theramex Announces Licensing Agreement with ObsEva for the Commercialisation of Linzagolix for the Treatment of Uterine Fibroids

Retrieved on: 
Thursday, February 10, 2022
Biotechnology, Women, Consumer, Health, Pharmaceutical, Patient, SIX Swiss Exchange, Birth certificate, Pregnancy, Abdominal pain, Leiomyoma, Anti–vascular endothelial growth factor therapy, Solution, Low back pain, Endometriosis, Uterine fibroid, Osteoporosis, Uterus, Woman, Linzagolix, Constipation, Birth, Nasdaq, Partnership, Gonadotropin-releasing hormone, Fertility, Physician, Fibroid, Menopause, Drug development, Pharmaceutical industry, Theramex, Theramex, ObsEva, THERAMEX, OBSEVA

Linzagolix is a GnRH receptor antagonist for the treatment of uterine fibroids.

Key Points: 
  • Linzagolix is a GnRH receptor antagonist for the treatment of uterine fibroids.
  • ObsEva is an ideal partner for Theramex given their focus on developing novel treatments to meet unmet medical needs of women suffering from uterine fibroids, endometriosis, and pre-term labour.
  • Uterine Fibroids affect 25% of women within reproductive age, many with severe symptoms requiring surgery.
  • By licensing Linzagolix we can potentially offer a new treatment option for physicians in managing women with uterine fibroids to provide symptomatic relief and delay or avoid surgery.

Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations

Retrieved on: 
Tuesday, February 8, 2022
Diosynth, Retinal, GLOBE, Senior, Growth, Blood, Eye, U.S. Securities and Exchange Commission, Biologics license application, Solution, PHSA, Terminology, Bevacizumab, SVP, Marketing, Bleeding, Annual report, Therapy, FDA, Patient, Retina, Anti–vascular endothelial growth factor therapy, GPO, BLA, Security (finance), VEGF, HUB, DME, SEC, Risk, Mab, Cerebral edema, Physician, AmerisourceBergen, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Food, Commercial Operating System (COS), AMD, Business development, BRVO, Group purchasing organization, COVID-19, Pharmaceutical industry, Fine chemical, Outlook

ISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.

Key Points: 
  • ISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.
  • Outlook Therapeutics is thrilled to welcome Joel to our executive leadership team.
  • Mr. Prieve added, I am delighted to join Outlook Therapeutics at such an important stage of its development.
  • I look forward to working with Jeff and the rest of the team on the potential commercial launch of ONS-5010.

Outlook Therapeutics Provides a Corporate Update and Business Outlook

Retrieved on: 
Tuesday, January 25, 2022
Securities and Exchange Commission (Philippines), Cerebral edema, Calendar, Physician, Mab, Anti–vascular endothelial growth factor therapy, SEC, PHSA, Security (finance), Annual report, Visual impairment, Patient, Eye, GLOBE, Diabetic retinopathy, Growth, Blood, Nasdaq, United States Public Health Service, Bleeding, Retinal, NEI, AMD, DME, Public Health Service Act, Special Protection Area, ...Continued, Safety, Program, Retina, Syringe, Marketing, Education, FDA, Diosynth, Bevacizumab, National Eye Institute, VEGF, COVID-19, Risk, Therapy, BRVO, BLA, Prescription, Awareness, Terminology, Pharmaceutical industry, Outlook

We look forward to an exciting year for Outlook Therapeutics and our continued efforts to bring ONS-5010 for wet AMD over the finish line.

Key Points: 
  • We look forward to an exciting year for Outlook Therapeutics and our continued efforts to bring ONS-5010 for wet AMD over the finish line.
  • In anticipation of potential approval, Outlook Therapeutics is conducting NORSE SEVEN to compare the safety of ONS-5010 in vials versus pre-filled syringes.
  • Outlook Therapeutics expects ONS-5010, if approved, to be a safe and cost-effective choice for patients, clinicians and payors worldwide for retinal indications.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway.

Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update

Retrieved on: 
Wednesday, December 22, 2021
Visual impairment, Annual report, AMD, ASRS, PHSA, Diosynth, Special Protection Area, COVID-19, Diabetic retinopathy, Annual conferences, Mab, National Eye Institute, GLOBE, Program, U.S. Securities and Exchange Commission, BVCA, Bleeding, Patient, Terminology, SEC, Annual general meeting, Eye, BRVO, OIS, Marketing, Physician, Society, Exercise, AAO, Public Health Service Act, Retina, VEGF, Safety, Therapy, Bevacizumab, Security (finance), Retinal, United States Public Health Service, Prescription, Calendar, Conference, Nasdaq, Cerebral edema, Anti–vascular endothelial growth factor therapy, NEI, Growth, Blood, DME, BLA, American Academy of Ophthalmology, Risk, Syringe, PH, FDA, Pharmaceutical industry, Outlook

In early August, Outlook Therapeutics reported positive top-line data from its NORSE TWO pivotal Phase 3 clinical trial.

Key Points: 
  • In early August, Outlook Therapeutics reported positive top-line data from its NORSE TWO pivotal Phase 3 clinical trial.
  • In anticipation of potential approval, Outlook Therapeutics is conducting NORSE SEVEN to compare the safety of ONS-5010 in vials versus pre-filled syringes.
  • At September 30, 2021, Outlook Therapeutics had cash and cash equivalents of $14.5 million.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway.

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

Retrieved on: 
Saturday, November 13, 2021
Therapy, CATT, Ranibizumab, Clinical trial, Security (finance), Terminology, National Eye, Growth, Calendar, COVID-19, Blood, Bleeding, DME, VEGF, PHSA, Visual acuity, Safety, Mab, Section, Retinal, Research, Section X, UCLA School of Dentistry, Annual conferences, Conference, U.S. Securities and Exchange Commission, GLOBE, Marketing, Patient, FDA, BRVO, PIER, Eye, CEO, Inflammation, TWO, Anti–vascular endothelial growth factor therapy, Retina, National Eye Institute, Macular degeneration, MD, David Geffen School of Medicine at UCLA, U.S. FDA, BLA, Risk, File association, Bevacizumab, AAO, Annual report, AMD, Cerebral edema, United States Public Health Service, Public Health Service Act, Physician, Â, Nasdaq, Month, Medical imaging, Pharmaceutical industry

ISELIN, N.J., Nov. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications, at the Retinal Subspecialty Day, AAO 2021 Annual Conference.

Key Points: 
  • It will be great for patients and their doctors to have more FDA-approved anti-VEGF options that are prepared specifically for intraocular use.
  • The NORSE TWO Phase 3 pivotal trial enrolled a total of228 wetAMD patients at 39 clinical trial sites inthe United States.
  • NORSE TWO data showed a strong safety profile, results consistent with previously reported safety data for ONS-5010, and similar to safety levels reported in prior research for bevacizumab used off-label in ophthalmology.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway.

Outlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab

Retrieved on: 
Tuesday, October 12, 2021
National Eye Institute, Therapy, BLA, VEGF, Safety, Terminology, BRVO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Public Health Service Act, Nasdaq, Retina, Incidence, Bevacizumab, Inflammation, Injection, Calendar, PHSA, Cerebral edema, COVID-19, Physician, Marketing, Growth, FDA, Vasculitis, U.S. Securities and Exchange Commission, Risk, United States Public Health Service, Anti–vascular endothelial growth factor therapy, Bleeding, BVCA, AMD, Food, Annual report, MD, Retinal, DME, Mab, Blood, GLOBE, MBA, CATT, Society, Security (finance), CEO, Eye, Patient, Pharmaceutical industry

If approved, ONS-5010 will offer retina specialists the first safe and effective, on-label bevacizumab that avoids the potentially serious adverse events associated with off-label repackaged IV bevacizumab from compounding pharmacies.

Key Points: 
  • If approved, ONS-5010 will offer retina specialists the first safe and effective, on-label bevacizumab that avoids the potentially serious adverse events associated with off-label repackaged IV bevacizumab from compounding pharmacies.
  • The study examined the frequency and incidence of adverse events as well as any changes in safety parameters.
  • In early August, Outlook Therapeutics reported positive topline data from its NORSE TWO pivotal Phase 3 clinical trial.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.